Industry Insights

31. Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy 8/25/2026

    Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

32. How Modern Logistics Support Belmont And HHS OIG Goals 8/24/2026

    Participant support can expand trial access, but regulatory uncertainty limits adoption. A safe harbor could enable reimbursement and compensation while protecting against coercion and undue influence.

33. FDA Finalizes Psychedelic Drug Guidance: What Sponsors Need To Know 8/24/2026

    FDA's July 2026 final guidance on psychedelic drug clinical investigations sets expectations for sponsors developing psilocybin, LSD, and MDMA therapies. Learn what it means for your program.

34. Hybrid And Decentralized CNS Clinical Trials: Finding The Right Balance 8/24/2026

    Decentralized and hybrid trial models are reshaping CNS research. Learn how to match virtual tools to your study design, endpoints, and patient population for better outcomes.

35. Ophthalmic Clinical Trials: Addressing Barriers To Enrollment And Retention 8/24/2026

    Ophthalmic trials lose participants at twice the rate of other studies. Point-of-need assessment delivery cuts dropout from 30% to 9% and reduces travel burden by 80.6%, protecting your endpoint data.

36. Accountability Gaps Can Break Clinical Supply Contracts 8/24/2026

    Contract gaps can create clinical supply failures when responsibilities differ across agreements. See how aligning obligations can prevent costly disputes, delays, and risks.

37. 4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations 8/24/2026

    Discover how AI-enhanced point-of-care diagnostics are changing trial design and what ClinOps should do next.

38. What BriaCell's Trial Design Says About Real-World Cancer Research 8/24/2026

    BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

39. Receptor Occupancy In The Era Of Multispecific Therapeutics 8/21/2026

    Receptor occupancy studies face new challenges as multispecific therapeutics introduce complex target engagement, receptor trafficking, cellular interactions, and assay interpretation considerations.

40. Sustainable Patient Engagement: Your Enrollment And Representation Depend On It 8/21/2026

    Early and ongoing patient engagement is a crucial component to staving off recruitment trouble and securing proper patient representation. Boehringer Ingelheim's Karen Correa, Ph.D., explains how.